Closed system drug transfer device

Newly Published Peer-Reviewed Study Shows Efficacy of Equashield CSTD in Preventing Hazardous Drug Contamination When Compounding Cytotoxic Medications in Real-World Setting

Retrieved on: 
Tuesday, August 24, 2021
Transfer, GEM, International Journal of Environmental Research and Public Health, Environmental Research, IV, PORT, CE, NIOSH, CSTD, Hospital, Effectiveness, Closed system drug transfer device, Canadian International Council, Risk, Leakage, Solution, Public health, FDA, Aerosol, Medical device, Pharmaceutical industry

The European study, Effectiveness of Closed System Drug Transfer Devices in Reducing Leakage during Antineoplastic Drugs Compounding , was published in the International Journal of Environmental Research and Public Health.

Key Points: 
  • The European study, Effectiveness of Closed System Drug Transfer Devices in Reducing Leakage during Antineoplastic Drugs Compounding , was published in the International Journal of Environmental Research and Public Health.
  • It revealed that, when compared to alternative closed systems, Equashield's CSTD is effective in eliminating spills and leakage during gemcitabine (GEM) compounding.
  • The study was conducted between 2016 and 2021 in the centralized cytotoxic drug preparation unit of a hospital in Genoa, Italy.
  • Equashield's product suite includes the EQUASHIELD Closed System Transfer Device (CSTD), and EQUASHIELD Pro, the first ever closed system-enabled Automated Pharmacy Compounding System.

Global Closed System Drug Transfer Device Market (2021 to 2028) - Share, Size, Trends, Industry Analysis Report - ResearchAndMarkets.com

Retrieved on: 
Thursday, April 29, 2021
Medical Supplies, Health, Closed system drug transfer device, Occupational safety and health, Natural sciences, Physical sciences, Chemistry, Hazardous drugs, Filtration

b'The "Closed System Drug Transfer Device Market Share, Size, Trends, Industry Analysis Report, By Type; By Component; By Closing Mechanism; By Technology; By End-Use; By Regions; Segment Forecast, 2021 - 2028" report has been added to ResearchAndMarkets.com\'s offering.\nThe global closed system drug transfer device market size is expected to reach USD 1.91 billion by 2028 according to a new study.

Key Points: 
  • b'The "Closed System Drug Transfer Device Market Share, Size, Trends, Industry Analysis Report, By Type; By Component; By Closing Mechanism; By Technology; By End-Use; By Regions; Segment Forecast, 2021 - 2028" report has been added to ResearchAndMarkets.com\'s offering.\nThe global closed system drug transfer device market size is expected to reach USD 1.91 billion by 2028 according to a new study.
  • Governments across the globe are investing significantly in the development of advanced healthcare infrastructure, boosting market growth of closed system drug transfer devices system.\nOn the basis of type, the market is segmented into filtration, and barrier machines.
  • Filtration segment are equipped with technology to clean the air passing between the environment and the hazardous drug vial.
  • Click-to-Lock closed system drug transfer devices are used to prevent prolonged exposure to hazardous drug vapors.

Fresenius Kabi Signs Exclusive U.S. Distribution Agreement with Corvida Medical for the HALO® Closed System Drug-Transfer Device

Retrieved on: 
Thursday, April 1, 2021
Research, Medical devices, Biotechnology, Health, Pharmaceutical, General Health, Other Science, Science, Oncology, Bad Homburg vor der Höhe, Fresenius, Societates Europaeae, CSTD, Video games, Halo, Germany, Companies, Closed system drug transfer device, Fresenius Kabi, Corvida Medical

View the full release here: https://www.businesswire.com/news/home/20210401005108/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20210401005108/en/
    Fresenius Kabi is now the exclusive U.S. distributor for Corvida Medical's HALO Closed System Drug-Transfer Device.
  • (Photo: Business Wire)
    Under the terms of the agreement, Fresenius Kabi will be the exclusive U.S. distributor for the HALO Closed System Drug-Transfer Device (CSTD).
  • The combination of Fresenius Kabi freeflex/freeflex+ IV solution containers, oncology medicines and Corvida Medicals HALO CSTD allows Fresenius Kabi to provide customers a broad range of products to assist with their oncology needs.
  • Mitch Moeller, CEO of Corvida Medical added, "We believe Fresenius Kabi is a great partner for the HALO Closed System Drug-Transfer Device.

Global $1.66 Billion Closed Systems Drug Transfer Devices Market Forecast to 2027 - ResearchAndMarkets.com

Retrieved on: 
Friday, November 27, 2020
Medical devices, Health, Occupational safety and health, Health, Medicine, Closed system drug transfer device, Hazardous drugs, COVID-19 pandemic, Diaphragm, Chemotherapy

The "Closed Systems Drug Transfer Devices Market Forecast to 2027 - COVID-19 Impact and Global Analysis by Closing Mechanism; Type; Technology; Component; End User, and Geography" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Closed Systems Drug Transfer Devices Market Forecast to 2027 - COVID-19 Impact and Global Analysis by Closing Mechanism; Type; Technology; Component; End User, and Geography" report has been added to ResearchAndMarkets.com's offering.
  • Based on technology, the global closed system drug transfer devices market is segmented into diaphragm-based devices, compartmentalized devices, and air cleaning/filtration devices.
  • The closed system drug transfer devices market is expected to grow owing to factors such as growing adoption of chemotherapy and improvement of regulatory guidelines regarding hazardous drugs.
  • The COVID-19 outbreak has also affected the closed system drug transfer devices market across the globe.

Europe Closed Systems Drug Transfer Devices Market Forecast to 2027 - COVID-19 Impact and Regional Analysis By Closing Mechanism, Type, Technology, Component, and End User and Country

Retrieved on: 
Wednesday, November 25, 2020
Occupational safety and health, Health sciences, Health, Clinical medicine, Closed system drug transfer device, Chemotherapy, Hazardous drugs

The closed systems drug transfer devices market in Europe is primarily driven by the growing adoption of closed systems drug transfer devices for chemotherapy and improvements in regulatory guidelines regarding hazardous drugs.However, the lack of standards and product safety issues hamper the growth of the market.

Key Points: 
  • The closed systems drug transfer devices market in Europe is primarily driven by the growing adoption of closed systems drug transfer devices for chemotherapy and improvements in regulatory guidelines regarding hazardous drugs.However, the lack of standards and product safety issues hamper the growth of the market.
  • Additionally, technological advancements in handling hazardous drugs and rising number of chemotherapeutic drug approvals are expected to fuel the growth of the Europe closed systems drug transfer devices market during the forecast period.
  • Closed system drug transfer devices provide protection against hazardous drugs or vapors during drug preparation and administration.These devices comprise components to filter dangerous vapors.
  • Furthermore, the luer-lock systems segment is expected to register the highest CAGR in the closed systems drug transfer devices market during the forecast period.

Equashield and Tosho Inc. Increase CSTD Adoption in Japan

Retrieved on: 
Monday, September 9, 2019
Pharmacy, Health, Pharmaceutical sciences, CSTD, Hazardous drugs, Compounding, Hospital pharmacy, Closed system drug transfer device

NEW YORK, Sept. 8, 2019 /PRNewswire/ -- Equashield (equashield.com), a leading provider of Closed System Transfer Devices (CSTDs) for hazardous drugs, announced today that, through Japanese distributor Tosho Inc. , the award-winning EQUASHIELD CSTD will now be available to oncology nurses in Japan.

Key Points: 
  • NEW YORK, Sept. 8, 2019 /PRNewswire/ -- Equashield (equashield.com), a leading provider of Closed System Transfer Devices (CSTDs) for hazardous drugs, announced today that, through Japanese distributor Tosho Inc. , the award-winning EQUASHIELD CSTD will now be available to oncology nurses in Japan.
  • This expansion is the result of an exclusive agreement between Tosho and IV tube manufacturer PAL Medical .
  • "Approximately 100 hospital pharmacies in Japan are currently utilizing the EQUASHIELD CSTD for their hazardous drug compounding, due to its superior quality, safety, and ease-of-use," said Jojo Kishimoto, General Manager for Tosho.
  • Equashield's product suite includes EQUASHIELD II, its flagship Closed System Transfer Device (CSTD), and EQUASHIELD Pro, the first ever closed system-enabled Automated Pharmacy Compounding System.

HOPA and ONS Collaborate on Safe Handling Guidelines Consistent with National Recommendations

Retrieved on: 
Tuesday, September 3, 2019
Health, Articles, Clinical pharmacology, Hazardous drugs, Pharmacy, Industrial hygiene, Safety engineering, Occupational safety and health, Occupational Safety and Health Administration, National Institute for Occupational Safety and Health, American Society of Health-System Pharmacists, Closed system drug transfer device

The joint position statement, entitled "Ensuring Healthcare Worker Safety When Handling Hazardous Drugs," is consistent withUSP , National Institute for Occupational Safety and Health (NIOSH), Occupational Safety and Health Administration (OSHA), andAmerican Society of Health-System Pharmacists (ASHP) recommendations.

Key Points: 
  • The joint position statement, entitled "Ensuring Healthcare Worker Safety When Handling Hazardous Drugs," is consistent withUSP , National Institute for Occupational Safety and Health (NIOSH), Occupational Safety and Health Administration (OSHA), andAmerican Society of Health-System Pharmacists (ASHP) recommendations.
  • The ONS Board of Directors approved the final version in July, and the HOPA Board of Directors approved it in August.
  • Find resources and tools to help you safely administer hazardous drugs in your practice, including the Safe Handling Basics course (free for ONS members), Safe Handling of Hazardous Drugs (third edition) and Toolkit for Safe Handling of Hazardous Drugs for Nurses in Oncology, at ons.org.
  • For specific questions about safe handling, email [email protected] or reach out to us on social media with the hashtag #ONSsafehandling.

Transfer Pharma Signs Partnership Agreement With Equashield to Provide Closed System Transfer Devices to Increase Hospital Safety in Romania

Retrieved on: 
Monday, June 3, 2019
Health, Pharmacy, Medicine, Occupational safety and health, CSTD, Compounding, Hazardous drugs, Cluj-Napoca, Chemotherapy, Pharma, Closed system drug transfer device

"The demand for chemotherapy drugs within Romania has risen, with over 120,000 patients currently needing cancer care," said Constantin Jelescu, CEO and Founder of Transfer Pharma Solutions.

Key Points: 
  • "The demand for chemotherapy drugs within Romania has risen, with over 120,000 patients currently needing cancer care," said Constantin Jelescu, CEO and Founder of Transfer Pharma Solutions.
  • Transfer Pharma has started providing Romanian health facilities with Equashield's CSTDs, beginning with the Emergency Military Hospital Dr. Constantin Papilian Cluj Napoca .
  • Equashield isa leading provider of manual and automated solutions for the compounding and administration of hazardous drugs.
  • Equashield's product suite includes EQUASHIELD II, its flagship Closed System Transfer Device (CSTD), and EQUASHIELD Pro, the first ever closed system-enabled Automated Pharmacy Compounding System.

Equashield and Max Care Medical to Distribute Leading Closed System Transfer Device in Middle East and North Africa

Retrieved on: 
Wednesday, October 3, 2018
Pharmacy, Health, Middle East, Western Asia, CSTD, Hazardous drugs, Compounding, Saudi Arabia, Closed system drug transfer device

Equashield (equashield.com), a leadingproviderofClosed System TransferDevices(CSTDs) for hazardous drugs, announced today a distribution partnership with Saudi Arabia-based Max Care Medical.

Key Points: 
  • Equashield (equashield.com), a leadingproviderofClosed System TransferDevices(CSTDs) for hazardous drugs, announced today a distribution partnership with Saudi Arabia-based Max Care Medical.
  • Max Care will market and sell Equashield's Closed System Transfer Device for the safe compounding of hazardous drugs in Saudi Arabia, as well as the wider Middle East and North Africa (MENA) region.
  • Max Care and Equashield will sponsor an educational symposium at the 5thannual GCC Pharmacy Congress.
  • Equashield's product suite includes EQUASHIELD II, its flagship Closed System Transfer Device (CSTD), and EQUASHIELD Pro, the first ever closed system-enabled multi-station hazardous drug compounder.